Key Takeaways
- Strong quarter, volume-led: Revenue grew 22.2% YoY to ₹441 crores, with India business up 22.9%, significantly outpacing IPM growth of ~12%. Organic growth excluding Wokadine was 21.5%.
- Chronic portfolio is the engine: Chronic business grew ~29%, nearly double the chronic market segment, driven by 33 engine brands that contribute ~79% of India revenue and are growing at 22%.
- PAT growth lagged revenue: PAT grew 15.3% YoY, held back by higher depreciation and amortisation from newly commissioned facilities and brand acquisitions, while EBITDA margin held stable at 21.7%.
- International is a slow build: Soft H1 performance reflects a B2B model with country-specific registration timelines; dossier preparation for hormone markets will take 2–3 years to bear fruit, and international will stay below 10% of revenue even after that.
- What to watch next quarter: Whether Wokadine’s slower-than-expected business-model change gains visibility, the IVF task force’s PCPM trajectory toward ₹8–9 lakh, and any concrete M&A movement in the five new therapy areas.
Revenue Growth & Volume Story
- Volume-led outperformance: Over the last 3 years, CORONA’s volume growth was 3.3x IPM, new introductions 2.2x, and price 1.2x, reinforcing a strategy built on expanding volumes and broadening the product basket rather than price-led expansion.
- Price growth accelerated: Price growth moved from ~5% historically to 8.9% in Q2 FY27, which management attributes to market absorption capacity, the competitive landscape, and active management on both NLEM and non-NLEM fronts.
- IPM growth drivers are unclear: Management cited loss of exclusivity on products and increased patient awareness as possible reasons for IPM acceleration to 10–12%, but admitted the true cause is unknown and the 10–12% expectation for coming quarters is “individual gut feel.”
- Patient footfall rising: An observed increase in patients at doctor cabins and corporate hospitals may be contributing to market growth, though the reason remains uncertain.
Nirav Mehta: “So, you know, nobody knows the reason, to be very honest. We are just predicting that this may be one of the reasons. So I am not an expert to comment on this, but I am expecting that IPM will continue to grow on 10%, at least in a quarter to come, looking at the current momentum.”
Engine Brands & Portfolio Strategy
- 33 engine brands dominate: These brands contribute ~79% of India business and grew at 22%, forming the core growth driver; management sees them as potential ₹100 crores-plus brands.
- Second pipeline identified: Another 33 important brands have been identified that could become engine brands, and they are receiving differentiated focus to build them toward the same scale.
- NLEM contribution declining: The NLEM portfolio’s share within CORONA has fallen from ~9% to 7.5%, reducing exposure to price-control risk even as management declined to comment specifically on regulatory scenarios.
- New division launched: A division added in Q4 FY26 is creating space for potential future engine brands to develop.
Nirav Mehta: “If we ever sell and we don't have a brand, I think we are in the wrong business if you talk about IPM and sustainable growth.”
Wokadine & IVF Task Force
- Wokadine integration slower than expected: The supply-chain and distribution integration is complete, but the business-model change is running behind plan; management expects the next 2 quarters to provide more visibility and remains confident in a 25% CAGR over 3–4 years.
- IVF task force performing: The 46 dedicated MRs deployed in CY2026 reached ~₹7 lakh PCPM in the first 6 months, covering ~2,500 doctors across ~80% of the market; year-end PCPM expectation is ₹8–9 lakh.
- No MR expansion near-term: No further MR additions are planned until at least FY28; if added, it would be ~150 people sometime in FY28, but the decision is not yet taken.
- MR addition margin impact fading: The 400+ MRs added in Q4 FY26 created an EBITDA drag that management expects to moderate, with margins improving in coming years.
Nirav Mehta: “The integration and change in business model are a little slower than expected. But the next 2 quarters will give us more visibility. We are still very confident in achieving 25% CAGR for Wokadine over 3 to 4 years.”
International Business
- Soft H1 is normal course: International growth has been soft in H1 and Q2 FY27, attributed to the B2B business model with different country-specific guidelines on market access and registration.
- Hormone push is a multi-year build: CORONA has built a hormone plant in Ahmedabad for forward integration, taken a stake in La Chandra (a hormonal API player) for backward integration, and is in advanced stages of preparing ~10–12 dossiers for regulated and semi-regulated markets.
- Revenue will stay small: Even after 2–3 years of dossier and registration work, international business will remain less than 10% of total revenue; FY27 international revenue is expected to close at ₹60–₹65 crores, then grow ~15% the following year.
- Regulatory clearances in place: EU GMP clearance was received in the last 2 quarters, and ANVISA clearance (Brazil) has also been secured, supporting the international dossier strategy.
Margins & Profitability
- EBITDA margin stable: Q2 EBITDA margin held at 21.7%, with H1 at 21.9%, up from the FY26 full-year margin of 20.9%.
- PAT growth moderated by non-cash charges: PAT grew 15.3% YoY, trailing revenue growth of 22.2%, primarily due to higher depreciation and amortisation from newly commissioned facilities and brand acquisitions.
- No margin guidance given: When asked about improving EBITDA margins to the mid-20s and a timeline, management stated they have never given operating margin guidance and only said margins will improve in coming years without confirming a target.
New Therapy Entry & M&A
- Five therapy areas targeted: CORONA will try to enter nephrology, neuropsychiatry, gastroenterology, spine, and rheumatology within 2–3 years, via organic or inorganic routes.
- Inorganic deals being evaluated: The company is working on deals for brands or small companies in these five new therapy areas to expedite entry, though nothing is concrete yet.
- MNC discussions in existing therapies: Separate M&A conversations are underway with MNCs, but these involve products in therapies where CORONA is already present, not the five new areas.
- Valuation approach is return-driven: Management does not think in terms of multiples but calculates what they can gain and how they can build the brand over 3–5 years, then offers a multiple accordingly.
Nirav Mehta: “We never try to think about the multiples which we are giving. We always try to calculate what we are going to gain from it and how our business model looks, how we plan to take this brand and move it for another 3 to 5 years, and how we can build it. Whatever our business plan suggests, then we try to give the multiple accordingly.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 1.5x IPM growth; IPM expected at lower double-digit (~10–12%), implying ~15%+ revenue growth | Next 3–4 quarters |
| PAT growth | 20% | FY27 |
| Wokadine CAGR | 25% CAGR over 3–4 years; next 2 quarters will give more visibility | 3–4 years |
| IVF task force PCPM | Year-end PCPM of ₹8–9 lakh | Year-end (implied FY27) |
| International FY27 revenue | Close at ₹60–₹65 crores | FY27 (stated in Q2 FY27 call) |
| International next-year growth | ~15% growth on FY27 base | Next year (implied FY28) |
| New therapy entry | Enter nephrology, neuropsychiatry, gastroenterology, spine, rheumatology | Within 2–3 years (for new therapies generally) |
| MR addition | ~150 people possible, not yet decided | Sometime in FY28 (conditional) |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹441 cr, +22.2% YoY |
| Revenue growth ex-Wokadine | 21.5% YoY |
| India business revenue growth | 22.9% YoY, 97% of total revenue |
| EBITDA | ₹96 cr, +22.3% YoY |
| EBITDA margin | 21.7%, stable YoY; FY26 full-year was 20.9% |
| PAT | ₹60 cr, +15.3% YoY |
| PAT margin | 13.7% |
| H1 FY27 ROCE | 49.8% |
| H1 FY27 ROE | 32.9% |
| Revenue guidance | 1.5x IPM growth, implying ~15% revenue growth if IPM grows ~10% |
| PAT guidance | 20% growth |
| MR count | 3,111, after adding ~400 MRs in Q4 FY26 |
| Engine brands (33) contribution | ~79% of India business, growing at 22% |
| CORONA IPM market share | 0.77% |
| Core therapies market share | ~2.3%, growing ~25% faster than IPM |
| NLEM portfolio contribution | ~7.5%, down from ~9% |
| International business revenue | ₹12.6 cr in Q2, FY27 guidance of ₹60–65 cr |
| IVF task force PCPM | ~₹7 lakh in first 6 months, year-end expectation ₹8–9 lakh |
| Price growth | 8.9% in Q2, vs historical ~5% from FY23–FY26 |